Rebuttal from Michel Bouvier and Terence E. Hébert.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. GPCRs and Signal Transducers: Interaction Stoichiometry.Trends in pharmacological sciences · 2018
   Review
2. Conformational biosensors reveal allosteric interactions between heterodimeric AT1 angiotensin and prostaglandin F2α receptors.The Journal of biological chemistry · 2017
   Article
3. Protease-activated receptors in hemostasis.Blood · 2016
   Review
4. Opioid receptors: Structural and mechanistic insights into pharmacology and signaling.European journal of pharmacology · 2015
   Review
5. Single-molecule analyses of fully functional fluorescent protein-tagged follitropin receptor reveal homodimerization and specific heterodimerization with lutropin receptor.Biology of reproduction · 2015
   Article

Corrections and comments

• Comment on
  CrossTalk opposing view: Weighing the evidence for class A GPCR dimers, the jury is still out.2014

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as